{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T13:31:34Z","timestamp":1793971894290,"version":"4.8.0"},"reference-count":111,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T00:00:00Z","timestamp":1617753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Mesothelin (MSLN) represents an attractive molecule for targeted cancer therapies. To identify tumors that might benefit from such therapies, tissue microarrays including 15,050 tumors from 122 different tumor types and 76 healthy organs were analyzed for MSLN expression by immunohistochemistry. Sixty-six (54%) tumor types showed at least occasional weak staining, including 50 (41%) tumor types with at least one strongly positive sample. Highest prevalence of MSLN positivity had ovarian carcinomas (serous 97%, clear cell 83%, endometrioid 77%, mucinous 71%, carcinosarcoma 65%), pancreatic adenocarcinoma (ductal 75%, ampullary 81%), endometrial carcinomas (clear cell 71%, serous 57%, carcinosarcoma 50%, endometrioid 45%), malignant mesothelioma (69%), and adenocarcinoma of the lung (55%). MSLN was rare in cancers of the breast (7% of 1138), kidney (7% of 807), thyroid gland (1% of 638), soft tissues (0.3% of 931), and prostate (0 of 481). High expression was linked to advanced pathological tumor (pT) stage (p &lt; 0.0001) and metastasis (p &lt; 0.0001) in 1619 colorectal adenocarcinomas, but unrelated to parameters of malignancy in 1072 breast-, 386 ovarian-, 174 lung-, 757 kidney-, 171 endometrial-, 373 gastric-, and 925 bladder carcinomas. In summary, numerous important cancer types with high-level MSLN expression might benefit from future anti-MSLN therapies, but MSLN\u2019s prognostic relevance appears to be limited.<\/jats:p>","DOI":"10.3390\/biomedicines9040397","type":"journal-article","created":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T11:31:59Z","timestamp":1617795119000},"page":"397","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":97,"title":["Mesothelin Expression in Human Tumors: A Tissue Microarray Study on 12,679 Tumors"],"prefix":"10.3390","volume":"9","author":[{"given":"S\u00f6ren","family":"Weidemann","sequence":"first","affiliation":[{"name":"Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20357 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Gagelmann","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20357 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Gorbokon","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20357 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1572-8200","authenticated-orcid":false,"given":"Maximilian","family":"Lennartz","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20357 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Menz","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20357 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas M.","family":"Luebke","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20357 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Kluth","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20357 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7542-4340","authenticated-orcid":false,"given":"Claudia","family":"Hube-Magg","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20357 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niclas C.","family":"Blessin","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20357 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Fraune","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20357 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"M\u00f6ller","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20357 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Bernreuther","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20357 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3652-532X","authenticated-orcid":false,"given":"Patrick","family":"Lebok","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20357 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4257-856X","authenticated-orcid":false,"given":"Till S.","family":"Clauditz","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20357 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Jacobsen","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20357 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob R.","family":"Izbicki","sequence":"additional","affiliation":[{"name":"General, Visceral and Thoracic Surgery Department and Clinic, University Medical Center Hamburg-Eppendorf, 20357 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Jansen","sequence":"additional","affiliation":[{"name":"General, Visceral and Thoracic Surgery Department and Clinic, University Medical Center Hamburg-Eppendorf, 20357 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Sauter","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20357 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ria","family":"Uhlig","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20357 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waldemar","family":"Wilczak","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20357 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Steurer","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20357 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Minner","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20357 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eike","family":"Burandt","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20357 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer H.","family":"Krech","sequence":"additional","affiliation":[{"name":"Institute of Pathology, Clinical Center Osnabrueck, 49074 Osnabrueck, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dum","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20357 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Till","family":"Krech","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20357 Hamburg, Germany"},{"name":"Institute of Pathology, Clinical Center Osnabrueck, 49074 Osnabrueck, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas H.","family":"Marx","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20357 Hamburg, Germany"},{"name":"Department of Pathology, Academic Hospital Fuerth, 90766 Fuerth, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0158-4258","authenticated-orcid":false,"given":"Ronald","family":"Simon","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20357 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,4,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1073\/pnas.93.1.136","article-title":"Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers","volume":"93","author":"Chang","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0021-9258(17)42180-6","article-title":"A novel cytokine exhibiting megakaryocyte potentiating activity from a human pancreatic tumor cell line HPC-Y","volume":"269","author":"Yamaguchi","year":"1994","journal-title":"J. Biol. Chem."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1006\/mcbr.2000.0181","article-title":"Structure of the Mesothelin\/MPF Gene and Characterization of Its Promoter","volume":"3","author":"Urwin","year":"2000","journal-title":"Mol. Cell Biol. Res. Commun."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/ijc.2910500308","article-title":"Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium","volume":"50","author":"Chang","year":"1992","journal-title":"Int. J. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"26744","DOI":"10.18632\/oncotarget.15814","article-title":"Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma","volume":"8","author":"Inaguma","year":"2017","journal-title":"Oncotarget"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.nano.2008.06.006","article-title":"Mesothelin is a specific biomarker of invasive cancer in the Barrett-associated adenocarcinoma progression model: Translational implications for diagnosis and therapy","volume":"4","author":"Alvarez","year":"2008","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/01.MP.0000056981.16578.C3","article-title":"Value of Mesothelin Immunostaining in the Diagnosis of Mesothelioma","volume":"16","year":"2003","journal-title":"Mod. Pathol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0046-8177(03)00177-1","article-title":"Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas","volume":"34","author":"Frierson","year":"2003","journal-title":"Hum. Pathol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1158\/1078-0432.CCR-04-2236","article-title":"Markers of Adenocarcinoma Characteristic of the Site of Origin: Development of a Diagnostic Algorithm","volume":"11","author":"Dennis","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1128\/MCB.20.8.2902-2906.2000","article-title":"Mesothelin Is Not Required for Normal Mouse Development or Reproduction","volume":"20","author":"Bera","year":"2000","journal-title":"Mol. Cell. Biol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1476-4598-5-50","article-title":"Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors","volume":"5","author":"Gubbels","year":"2006","journal-title":"Mol. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1074\/jbc.M806776200","article-title":"A Binding Domain on Mesothelin for CA125\/MUC","volume":"284","author":"Kaneko","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1158\/1541-7786.MCR-19-0688","article-title":"Mesothelin Enhances Tumor Vascularity in Newly Forming Pancreatic Peritoneal Metastases","volume":"18","author":"Avula","year":"2019","journal-title":"Mol. Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/1476-4598-10-106","article-title":"Mesothelin confers pancreatic cancer cell resistance to TNF-alpha-induced apoptosis through Akt\/PI3K\/NF-kappaB activation and IL-6\/Mcl-1 overexpression","volume":"10","author":"Bharadwaj","year":"2011","journal-title":"Mol. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1042\/BJ20110282","article-title":"Mesothelin enhances invasion of ovarian cancer by inducing MMP-7 through MAPK\/ERK and JNK pathways","volume":"442","author":"Chang","year":"2012","journal-title":"Biochem. J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1042\/BJ20082196","article-title":"Mesothelin inhibits paclitaxel-induced apoptosis through the PI3K pathway","volume":"424","author":"Chang","year":"2009","journal-title":"Biochem. J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-017-0633-8","article-title":"Mesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells","volume":"16","author":"He","year":"2017","journal-title":"Mol. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1158\/1078-0432.CCR-11-2614","article-title":"Mesothelin Overexpression Promotes Mesothelioma Cell Invasion and MMP-9 Secretion in an Orthotopic Mouse Model and in Epithelioid Pleural Mesothelioma Patients","volume":"18","author":"Servais","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1158\/1541-7786.MCR-07-0254","article-title":"Mesothelin Promotes Anchorage-Independent Growth and Prevents Anoikis via Extracellular Signal-Regulated Kinase Signaling Pathway in Human Breast Cancer Cells","volume":"6","author":"Uehara","year":"2008","journal-title":"Mol. Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1177\/030006051204000608","article-title":"Mesothelin Promotes Invasion and Metastasis in Breast Cancer Cells","volume":"40","author":"Wang","year":"2012","journal-title":"J. Int. Med Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/1756-9966-31-84","article-title":"Mesothelin regulates growth and apoptosis in pancreatic cancer cells through p53-dependent and -independent signal pathway","volume":"31","author":"Zheng","year":"2012","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1097\/00000478-200311000-00003","article-title":"Application of Mesothelin Immunostaining in Tumor Diagnosis","volume":"27","year":"2003","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.molonc.2016.07.003","article-title":"Characterization of a re-engineered, mesothelin-targeted Pseudomonas exotoxin fusion protein for lung cancer therapy","volume":"10","author":"Bauss","year":"2016","journal-title":"Mol. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/j.ymthe.2019.07.015","article-title":"Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers","volume":"27","author":"Haas","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"5787","DOI":"10.1158\/1078-0432.CCR-19-0070","article-title":"Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma","volume":"25","author":"Hassan","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1200\/JCO.19.02085","article-title":"First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors","volume":"38","author":"Hassan","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"5927","DOI":"10.1158\/1078-0432.CCR-14-0804","article-title":"Phase II Clinical Trial of Amatuximab, a Chimeric Antimesothelin Antibody with Pemetrexed and Cisplatin in Advanced Unresectable Pleural Mesothelioma","volume":"20","author":"Hassan","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"eaaz7252","DOI":"10.1126\/scitranslmed.aaz7252","article-title":"Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti\u2013PD-1 antibody in patients with mesothelioma and mouse tumor models","volume":"12","author":"Jiang","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Kim, H., Gao, W., and Ho, M. (2013). Novel Immunocytokine IL12-SS1 (Fv) Inhibits Mesothelioma Tumor Growth in Nude Mice. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0081919"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/mt.2011.256","article-title":"Redirected Antitumor Activity of Primary Human Lymphocytes Transduced With a Fully Human Anti-mesothelin Chimeric Receptor","volume":"20","author":"Lanitis","year":"2012","journal-title":"Mol. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s00404-020-05734-9","article-title":"Favorable therapeutic response after anti-Mesothelin antibody\u2013drug conjugate treatment requires high expression of Mesothelin in tumor cells","volume":"302","author":"Lazzerini","year":"2020","journal-title":"Arch. Gynecol. Obstet."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"33844","DOI":"10.18632\/oncotarget.26117","article-title":"The anti-mesothelin monoclonal antibody amatuximab enhances the anti-tumor effect of gemcitabine against mesothelin-high expressing pancreatic cancer cells in a peritoneal metastasis mouse model","volume":"9","author":"Mizukami","year":"2018","journal-title":"Oncotarget"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1158\/1535-7163.MCT-14-0487-T","article-title":"An Antimesothelin-Monomethyl Auristatin E Conjugate with Potent Antitumor Activity in Ovarian, Pancreatic, and Mesothelioma Models","volume":"13","author":"Scales","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1158\/1535-7163.MCT-16-0449","article-title":"Preclinical Efficacy of an Antibody-Drug Conjugate Targeting Mesothelin Correlates with Quantitative 89Zr-ImmunoPET","volume":"16","author":"Ogasawara","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1158\/1535-7163.MCT-15-0693","article-title":"Phase I Study of DMOT4039A, an Antibody\u2013Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer","volume":"15","author":"Weekes","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"141","DOI":"10.7150\/jca.1.141","article-title":"Mesothelin as a Potential Therapeutic Target in Human Cholangiocarcinoma","volume":"1","author":"Yu","year":"2010","journal-title":"J. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1440-1827.2007.02080.x","article-title":"Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma","volume":"57","author":"Kushitani","year":"2007","journal-title":"Pathol. Int."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/00000478-200302000-00002","article-title":"Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: An immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura","volume":"27","author":"Miettinen","year":"2003","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1097\/00000478-200308000-00001","article-title":"The immunohistochemical diagnosis of mesothelioma: A comparative study of epithelioid mesothelioma and lung adenocarcinoma","volume":"27","author":"Ordonez","year":"2003","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ejso.2018.10.050","article-title":"Biomarker panel predicts survival after resection in pancreatic ductal adenocarcinoma: A multi-institutional cohort study","volume":"45","author":"Nahm","year":"2019","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1309\/F1B64CL7H8VJKEAF","article-title":"Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis","volume":"124","author":"Hassan","year":"2005","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00428-018-02514-4","article-title":"Mesothelin expression has prognostic value in stage IotaIota\/IotaIotaIota colorectal cancer","volume":"474","author":"Shiraishi","year":"2019","journal-title":"Virchows Arch."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/PAI.0000000000000292","article-title":"Mesothelin Expression in Advanced Gastroesophageal Cancer Represents a Novel Target for Immunotherapy","volume":"24","author":"Illei","year":"2016","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1007\/s12325-020-01520-w","article-title":"Mesothelin Expression in Patients with High-Grade Serous Ovarian Cancer Does Not Predict Clinical Outcome But Correlates with CD11c+ Expression in Tumor","volume":"37","author":"Magalhaes","year":"2020","journal-title":"Adv. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1634\/theoncologist.2018-0896","article-title":"Mesothelin Expression Is a Predictive Factor for Peritoneal Recurrence in Curatively Resected Stage III Gastric Cancer","volume":"24","author":"Shin","year":"2019","journal-title":"Oncologist"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s10549-014-3077-5","article-title":"Mesothelin expression is associated with poor outcomes in breast cancer","volume":"147","author":"Li","year":"2014","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_47","first-page":"1","article-title":"Membrane mesothelin expression positivity is associated with poor clinical outcome of luminal\u2011type breast cancer","volume":"20","author":"Suzuki","year":"2020","journal-title":"Oncol. Lett."},{"key":"ref_48","first-page":"53","article-title":"Tissue Microarrays","volume":"1381","author":"Dancau","year":"2016","journal-title":"Adv. Struct. Saf. Stud."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/nm0798-844","article-title":"Tissue microarrays for high-throughput molecular profiling of tumor specimens","volume":"4","author":"Kononen","year":"1998","journal-title":"Nat. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13059-014-0560-6","article-title":"Gateways to the FANTOM5 promoter level mammalian expression atlas","volume":"16","author":"Lizio","year":"2015","journal-title":"Genome Biol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"D752","DOI":"10.1093\/nar\/gky1099","article-title":"Update of the FANTOM web resource: Expansion to provide additional transcriptome atlases","volume":"47","author":"Lizio","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/ng.2653","article-title":"The Genotype-Tissue Expression (GTEx) project","volume":"45","author":"Consortium","year":"2013","journal-title":"Nat. Genet."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1158\/1078-0432.CCR-05-1397","article-title":"Diffuse Mesothelin Expression Correlates with Prolonged Patient Survival in Ovarian Serous Carcinoma","volume":"12","author":"Yen","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"601","DOI":"10.5858\/arpa.2011-0326-OA","article-title":"Reevaluation and Identification of the Best Immunohistochemical Panel (pVHL, Maspin, S100P, IMP-3) for Ductal Adenocarcinoma of the Pancreas","volume":"136","author":"Liu","year":"2012","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.humpath.2014.03.006","article-title":"Diagnostic utility of immunohistochemistry in distinguishing between epithelioid pleural mesotheliomas and breast carcinomas: A comparative study","volume":"45","author":"Sahin","year":"2014","journal-title":"Hum. Pathol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"77872","DOI":"10.18632\/oncotarget.20845","article-title":"Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: Expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1","volume":"8","author":"Eguchi","year":"2017","journal-title":"Oncotarget"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/bjc.2012.235","article-title":"Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer","volume":"107","author":"Einama","year":"2012","journal-title":"Br. J. Cancer"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/jso.22024","article-title":"Mesothelin expression correlates with prolonged patient survival in gastric cancer","volume":"105","author":"Baba","year":"2011","journal-title":"J. Surg. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1158\/1055-9965.EPI-11-0993","article-title":"Tissue and Serum Mesothelin Are Potential Markers of Neoplastic Progression in Barrett\u2019s Associated Esophageal Adenocarcinoma","volume":"21","author":"Rizk","year":"2012","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"6132","DOI":"10.1158\/1078-0432.CCR-10-2275","article-title":"Phase I Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody MORAb-009 in Patients with Mesothelin-Expressing Cancers","volume":"16","author":"Hassan","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"5274","DOI":"10.1158\/1078-0432.CCR-09-0062","article-title":"Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P","volume":"15","author":"Kreitman","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1158\/1078-0432.CCR-19-3978","article-title":"Evaluation of Cyclophosphamide\/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer","volume":"26","author":"Tsujikawa","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"4936","DOI":"10.1002\/cncr.33145","article-title":"Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin","volume":"126","author":"Hassan","year":"2020","journal-title":"Cancer"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3892\/or.2013.2803","article-title":"ERC\/mesothelin is expressed in human gastric cancer tissues and cell lines","volume":"31","author":"Ito","year":"2014","journal-title":"Oncol. Rep."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.clbc.2013.05.001","article-title":"Mesothelin Expression and Survival Outcomes in Triple Receptor Negative Breast Cancer","volume":"13","author":"Parinyanitikul","year":"2013","journal-title":"Clin. Breast Cancer"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1177\/147323001204000309","article-title":"Clinicopathological Significance of Mesothelin Expression in Invasive Breast Cancer","volume":"40","author":"Wang","year":"2012","journal-title":"J. Int. Med. Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.humpath.2003.10.012","article-title":"Analysis of novel tumor markers in pancreatic and biliary carcinomas using tissue microarrays","volume":"35","author":"Swierczynski","year":"2004","journal-title":"Hum. Pathol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/00129039-200309000-00006","article-title":"Novel Markers of Pancreatic Adenocarcinoma in Fine-Needle Aspiration: Mesothelin and Prostate Stem Cell Antigen Labeling Increases Accuracy in Cytologically Borderline Cases","volume":"11","author":"McCarthy","year":"2003","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"ref_69","first-page":"3862","article-title":"Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: Identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE)","volume":"7","author":"Argani","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1309\/AJCPDTTL2I5ECMFG","article-title":"Mesothelin Expression in Pancreatic Mucinous Cysts","volume":"142","author":"Frank","year":"2014","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1309\/CEV30BE088CBDQD9","article-title":"Biomarkers in Diagnosis of pancreatic carcinoma in fine-needle aspirates","volume":"126","author":"Jhala","year":"2006","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/dc.21684","article-title":"The usefulness of S100P, mesothelin, fascin, prostate stem cell antigen, and 14-3-3 sigma in diagnosing pancreatic adenocarcinoma in cytological specimens obtained by endoscopic ultrasound guided fine-needle aspiration","volume":"42","author":"Dim","year":"2011","journal-title":"Diagn. Cytopathol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/01.pai.00000141545.36485.d6","article-title":"Localization of Mesothelin in Epithelial Ovarian Cancer","volume":"13","author":"Hassan","year":"2005","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"122","DOI":"10.4132\/jptm.2016.11.18","article-title":"Mesothelin Expression in Gastric Adenocarcinoma and Its Relation to Clinical Outcomes","volume":"51","author":"Han","year":"2017","journal-title":"J. Pathol. Transl. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"422","DOI":"10.7150\/ijms.39012","article-title":"Overexpression of Mesothelin in Pancreatic Ductal Adenocarcinoma (PDAC)","volume":"17","author":"Le","year":"2020","journal-title":"Int. J. Med. Sci."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.prp.2016.01.007","article-title":"Diagnostic value of IMP3 and mesothelin in differentiating pancreatic ductal adenocarcinoma from chronic pancreatitis","volume":"212","author":"Ibrahim","year":"2016","journal-title":"Pathol. Res. Pract."},{"key":"ref_77","first-page":"157","article-title":"Pancreatic metastases of renal clear cell carcinoma: A clinicopathological study of 11 cases with special emphasis on the usefulness of PAX2 and mesothelin for the distinction from primary ductal adenocarcinoma of the pancreas","volume":"35","author":"Gnemmi","year":"2013","journal-title":"Anal. Quant. Cytopathol. Histopathol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1177\/1066896911409575","article-title":"Mesothelin and GPR30 Staining Among a Spectrum of Pancreatic Epithelial Neoplasms","volume":"19","author":"Glass","year":"2011","journal-title":"Int. J. Surg. Pathol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/PGP.0b013e3181bbbcc1","article-title":"Primary Ovarian Mucinous Carcinoma of Intestinal Type: Significance of Pattern of Invasion and Immunohistochemical Expression Profile in a Series of 31 Cases","volume":"29","author":"Tabrizi","year":"2010","journal-title":"Int. J. Gynecol. Pathol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/PGP.0b013e31817d5340","article-title":"Distinguishing Breast Carcinoma From M\u00fcllerian Serous Carcinoma With Mammaglobin and Mesothelin","volume":"27","author":"Kanner","year":"2008","journal-title":"Int. J. Gynecol. Pathol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/dc.20747","article-title":"Utility of WT-1, p63, MOC31, mesothelin, and cytokeratin (K903 and CK5\/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma in effusions","volume":"36","author":"Pu","year":"2008","journal-title":"Diagn. Cytopathol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1111\/j.1365-2559.2007.02874.x","article-title":"Diagnostic value of cytokeratin 7, CD10 and mesothelin in distinguishing ovarian clear cell carcinoma from metastasis of renal clear cell carcinoma","volume":"51","author":"Leroy","year":"2007","journal-title":"Histopathology"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/j.1365-2559.2005.02279.x","article-title":"The use of the monoclonal antibody mesothelin in the diagnosis of malignant mesothelioma in pleural biopsies","volume":"48","author":"Galloway","year":"2006","journal-title":"Histopathology"},{"key":"ref_84","first-page":"67","article-title":"Expression of mesothelin, fascin, and prostate stem cell antigen in primary ovarian mucinous tumors and their utility in differentiating primary ovarian mucinous tumors from metastatic pancreatic mucinous carcinomas in the ovary","volume":"24","author":"Cao","year":"2005","journal-title":"Int. J. Gynecol. Pathol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.humpath.2003.11.013","article-title":"The diagnostic utility of immunohistochemistry in distinguishing between mesothelioma and renal cell carcinoma: A comparative study","volume":"35","year":"2004","journal-title":"Hum. Pathol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1053\/j.humpath.2003.07.002","article-title":"Expression of calretinin and other mesothelioma-related markers in thymic carcinoma and thymoma","volume":"34","author":"Pan","year":"2003","journal-title":"Hum. Pathol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"164","DOI":"10.9738\/INTSURG-D-13-00001.1","article-title":"Mesothelin Expression Is a Prognostic Factor in Cholangiocellular Carcinoma","volume":"98","author":"Nomura","year":"2013","journal-title":"Int. Surg."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.4161\/cbt.7.10.6562","article-title":"Nanoparticulate delivery of diphtheria toxin DNA effectively kills Mesothelin expressing pancreatic cancer cells","volume":"7","author":"Showalter","year":"2008","journal-title":"Cancer Biol. Ther."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"651","DOI":"10.4161\/cbt.3.7.919","article-title":"Gene expression profiling identifies markers of ampullary adenocarcinoma","volume":"3","author":"Maitra","year":"2004","journal-title":"Cancer Biol. Ther."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.canlet.2004.10.013","article-title":"Forced expression of deltaN-TCF-1B in colon cancer derived cell lines is accompanied by the induction of CEACAM5\/6 and mesothelin","volume":"223","author":"Liebig","year":"2005","journal-title":"Cancer Lett."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/modpathol.3800544","article-title":"The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: A comparative study","volume":"19","author":"Ordonez","year":"2006","journal-title":"Mod. Pathol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"10043","DOI":"10.2147\/OTT.S216362","article-title":"Prevalence of DLL3, CTLA-4 and MSTN Expression in Patients with Small Cell Lung Cancer","volume":"12","author":"Regzedmaa","year":"2019","journal-title":"OncoTargets Ther."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.pathol.2018.05.002","article-title":"Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: Prognostic implications","volume":"50","author":"Forest","year":"2018","journal-title":"Pathology"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.humpath.2010.03.002","article-title":"Mesothelin (MSLN) promoter is hypomethylated in malignant mesothelioma, but its expression is not associated with methylation status of the promoter","volume":"41","author":"Tan","year":"2010","journal-title":"Hum. Pathol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.ygyno.2006.10.063","article-title":"Overexpression of folate binding protein and mesothelin are associated with uterine serous carcinoma","volume":"105","author":"Dainty","year":"2007","journal-title":"Gynecol. Oncol."},{"key":"ref_96","first-page":"1549","article-title":"High expression of mesothelin in advanced serous ovarian cancer is associated with poor prognosis","volume":"24","author":"Yildiz","year":"2019","journal-title":"J. BUON"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.humpath.2004.04.014","article-title":"Expression of candidate tumor markers in ovarian carcinoma and benign ovary: Evidence for a link between epithelial phenotype and neoplasia","volume":"35","author":"Drapkin","year":"2004","journal-title":"Hum. Pathol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1309\/37RTWYAEPABYY410","article-title":"S100A4 protein and mesothelin expression in dysplasia and carcinoma of the extrahepatic bile duct","volume":"127","author":"Zhao","year":"2007","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_99","first-page":"1741","article-title":"Diffuse mesothelin expression leads to worse prognosis through enhanced cellular proliferation in colorectal cancer","volume":"19","author":"Inoue","year":"2020","journal-title":"Oncol. Lett."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00428-020-02775-y","article-title":"Prognostic significance of mesothelin expression in colorectal cancer disclosed by area-specific four-point tissue microarrays","volume":"477","author":"Shiraishi","year":"2020","journal-title":"Virchows Arch. Pathol. Anat. Physiol. Klin. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s12253-016-0060-y","article-title":"Aberrant Expression of Calretinin, D2\u201340 and Mesothelin in Mucinous and Non-Mucinous Colorectal Carcinomas and Relation to Clinicopathological Features and Prognosis","volume":"22","author":"Foda","year":"2016","journal-title":"Pathol. Oncol. Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1097\/MPA.0b013e318221bed8","article-title":"Co-Expression of Mesothelin and CA125 Correlates With Unfavorable Patient Outcome in Pancreatic Ductal Adenocarcinoma","volume":"40","author":"Einama","year":"2011","journal-title":"Pancreas"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.3892\/ijo.2012.1662","article-title":"Intracellular localization of mesothelin predicts patient prognosis of extrahepatic bile duct cancer","volume":"41","author":"Kawamata","year":"2012","journal-title":"Int. J. Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00535-013-0773-6","article-title":"C-ERC\/mesothelin provokes lymphatic invasion of colorectal adenocarcinoma","volume":"49","author":"Kawamata","year":"2013","journal-title":"J. Gastroenterol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s40291-017-0255-2","article-title":"Correlation Between Tumor Mesothelin Expression and Serum Mesothelin in Patients with Epithelial Ovarian Carcinoma: A Potential Noninvasive Biomarker for Mesothelin-targeted Therapy","volume":"21","author":"Hanaoka","year":"2017","journal-title":"Mol. Diagn. Ther."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"11694","DOI":"10.18632\/oncotarget.3429","article-title":"High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis","volume":"6","author":"Thomas","year":"2015","journal-title":"Oncotarget"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.biopha.2015.01.019","article-title":"Prognostic value of mesothelin expression in patients with triple negative and HER2-positive breast cancers","volume":"70","author":"Bayoglu","year":"2015","journal-title":"Biomed. Pharmacother."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"110","DOI":"10.18632\/genesandcancer.104","article-title":"MUC16 contributes to the metastasis of pancreatic ductal adenocarcinoma through focal adhesion mediated signaling mechanism","volume":"7","author":"Muniyan","year":"2016","journal-title":"Genes Cancer"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"El-Behaedi, S., Landsman, R., Rudloff, M., Kolyvas, E., Albalawy, R., Zhang, X., Bera, T., Collins, K., Kozlov, S., and Alewine, C. (2018). Protein Synthesis Inhibition Activity of Mesothelin Targeting Immunotoxin LMB-100 Decreases Concentrations of Oncogenic Signaling Molecules and Secreted Growth Factors. Toxins, 10.","DOI":"10.3390\/toxins10110447"},{"key":"ref_110","first-page":"srep01870","article-title":"Mesothelin Binding to CA125\/MUC16 Promotes Pancreatic Cancer Cell Motility and Invasion via MMP-7 Activation","volume":"3","author":"Chen","year":"2013","journal-title":"Sci. Rep."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1369\/jhc.2008.952770","article-title":"A Guide to the Perplexed on the Specificity of Antibodies","volume":"57","author":"Saper","year":"2008","journal-title":"J. Histochem. Cytochem."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/9\/4\/397\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T14:11:58Z","timestamp":1760364718000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/9\/4\/397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,7]]},"references-count":111,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,4]]}},"alternative-id":["biomedicines9040397"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines9040397","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,7]]}}}